 SeV is not likely to evolve into a pathogenic strain or into a virus with decreased oncolytic potential.The cytoplasmic replication of the virus results in a lack of host genome integration and recombination, which makes SeV safer and more attractive candidate for broadly used therapeutic oncolysis compared to some DNA viruses or retroviruses.One of the great advantages of the Sendai virus as a potential oncolytic agent is its safety.